Form 8-K - Current report:
SEC Accession No. 0001104659-22-096057
Filing Date
2022-08-30
Accepted
2022-08-30 16:30:22
Documents
15
Period of Report
2022-08-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2224757d1_8k.htm   iXBRL 8-K 36164
2 EXHIBIT 4.1 tm2224757d1_ex4-1.htm EX-4.1 58317
3 EXHIBIT 10.1 tm2224757d1_ex10-1.htm EX-10.1 71872
4 EXHIBIT 99.1 tm2224757d1_ex99-1.htm EX-99.1 15586
  Complete submission text file 0001104659-22-096057.txt   399632

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA jagx-20220824.xsd EX-101.SCH 3063
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20220824_lab.xml EX-101.LAB 34476
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20220824_pre.xml EX-101.PRE 22615
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2224757d1_8k_htm.xml XML 3604
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 221214917
SIC: 2834 Pharmaceutical Preparations